Inve India ▾

Sudeep Pharma share price & results

Sudeep Pharma Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Vadodara-based maker of mineral excipients & specialty ingredients for pharma/nutrition; entering battery-grade iron phosphate.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue106 ₹ crore+32.5% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin37.0 %−1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit34.0 ₹ crore+36.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity26.79 %−7.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-7.48 %−4.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)23.18 %+18.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 2 judged targets kept · 19 open · verdicts reflect calls analysed to Q1 FY27.

Sudeep Pharma Limited management guidance track record on Inve: 21 targets tracked across analysed earnings calls (1 achieved, 1 missed, 19 open).

TargetOriginal wordingSaidLatest callVerdict
Revenue GrowthSustain 26% growth for the remainder of the year.
Call transcript, Q2 FY26 · 22 Dec 2025		Q2 FY26Q1 FY27:Promise concluded in the previous fiscal year (FY26).
Call transcript, Q1 FY27 · 5 Aug 2026		Achieved*
EBITDA MarginMaintain above 35% going forward.
Call transcript, Q2 FY26 · 22 Dec 2025		Q2 FY26Q1 FY27:Q1 FY27 EBITDA margin was 34.7%, remaining below the original >35% target.
Call transcript, Q1 FY27 · 5 Aug 2026		Missed
Working Capital DaysModerate and sustain approximately around 140 to 150 days over the medium term.
Call transcript, Q2 FY26 · 22 Dec 2025		Q2 FY26Q1 FY27:Management revised near-term working capital target to 170 days (ex-battery), a dilution from the original 140-150 day medium-term goal.
Call transcript, Q1 FY27 · 5 Aug 2026		Revised Down

Source: Inve Guidance Tracker for Sudeep Pharma Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Sudeep Pharma Limited's 21 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 18 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹983 +1.74% · +₹16.8

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +27.0% 1Y

₹0.6k₹0.8k₹1.0k₹1.2k₹1.4kNov 25Jan 26Feb 26Apr 26May 26Jun 26Aug 26Sept 26Oct 26Q2 FY26 — 22 Dec 2025Q3 FY26 — 9 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 5 Aug 2026

1Y: ₹774.15 on 28 Nov 2025 → ₹983. High ₹1,344.2 (8 Sept 2026), low ₹530 (20 Jan 2026).

Previous close
₹966.2
Market cap
₹11.1k Cr
52-week range
₹530 – ₹1,344.2
Price to earnings (TTM to Jun 2026)
60.33×
Return on equity (TTM to Jun 2026)
26.79%

Overview

Symbol
NSE:SUDEEPPHRM
Exchange
NSE
Currency
INR

What Sudeep Pharma Limited does

Based on the company's own presentations, annual report and earnings calls.

Sudeep Pharma manufactures mineral-based pharmaceutical excipients, fortificants and specialty nutrition ingredients (calcium and iron compounds, magnesium stearate, encapsulated and liposomal blends, premixes) used by pharma, food and nutrition companies worldwide. It earns by selling these ingredients to a global customer base spanning pharmaceutical, infant/medical/sports nutrition and functional-food manufacturers, supported by its own manufacturing units, global sales offices and warehouses. Through its wholly owned subsidiary Sudeep Pharma B.V. it acquired Nutrition Supplies Services (NSS) in Europe to expand its formulation and nutrition-market reach, and through Sudeep Advanced Materials it is building a new battery-grade iron phosphate business for the EV/energy-storage supply chain.

Segments

  • Pharma, Food & Nutrition
  • Specialty Ingredients
  • Battery Materials (Sudeep Advanced Materials)
Manufacturing sites
5 (4 in India at Nandesari, plus 1 in Ireland via the NSS acquisition)
Combined annual manufacturing capacity
~1,23,000 MT (incl. upcoming Nandesari facility)
Permanent employees
770+
Customers
1,120+ across ~100 countries
Product portfolio
100+ products across pharma, food & nutrition, specialty ingredients and battery materials
Global warehouses
15 (USA, Europe, Africa, Asia)
Founded 1989Headquarters Vadodara, Gujarat, India Company website

How the price took the results

close before → close after

Q1 FY27
+10.0%
5 Aug
Q4 FY26
+0.8%
22 May
Q3 FY26
+3.3%
9 Feb
Q2 FY26
−3.3%
22 Dec

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sudeep Pharma Limited

Free account: one company. Everything above stays public.

Write why you follow Sudeep Pharma Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sudeep Pharma Limited

Guides on how to read this kind of business and the numbers that matter.